Biodistribution and dosimetry of [177Lu]Lu-SibuDAB in patients with metastatic castration-resistant prostate cancer
[<sup>177</sup>Lu]Lu-SibuDAB showed a prolonged blood circulation time and, hence, a significantly increased absorbed tumour dose, while tumour-to-organ ADC ratios were similar to conventional PSMA radiopharmaceuticals. Further clinical investigations to evaluate the efficacy and safety of [<sup>177</sup>Lu]Lu-SibuDAB are, thus, warranted.
Authors
- Cristian Soza‐Ried
- Vasko Kramer (ORCID: https://orcid.org/0000-0002-5285-6447)
- Heinz Nicolai (ORCID: https://orcid.org/0000-0002-1916-2291)
- Philipp Ritt
- Konstantin Zhernosekov
- Roger Schibli (ORCID: https://orcid.org/0000-0002-1537-3833)
- Amanda Rotger
- Ana Katrina Mapanao (ORCID: https://orcid.org/0000-0002-6045-7999)
- Korbinian Krieger (ORCID: https://orcid.org/0000-0002-5649-0710)
- René Fernández (ORCID: https://orcid.org/0000-0002-0426-8536)
- Horacio Amaral (ORCID: https://orcid.org/0000-0003-1633-2125)
- Cristina Müller (ORCID: https://orcid.org/0000-0001-9357-9688)
Institutions
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- ETH Zurich (CH)
- Isotopen Technologien München (Germany) (DE)
- Hospital San Borja Arriarán (CL)
Publication Details
- Journal
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2025-02-03
- DOI
- https://doi.org/10.1007/s00259-025-07102-8
- Citations
- 8
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 12.15
Funders
- European Commission
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung